- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04891042
Isthmocele Development Due to Primary Cesarean Section at The Latent or Active Phase (Isthmocele)
May 12, 2021 updated by: Resul Karakuş, Zeynep Kamil Maternity and Pediatric Research and Training Hospital
The Importance of Isthmocele Development Due to Primary Cesarean Section at The Latent or Active Phase of Labour
The importance of isthmocele development due to primary cesarean section at the latent or active phase of labour
Study Overview
Status
Recruiting
Conditions
Detailed Description
The dates between February 2021 to December 2021 , primiparous (primigravida) and multiparous (multigravida) patients who were hospitalized for delivery between 32 and 41 weeks of gestation and who haven't received cesarean in their previous delivery will be included in the study in Zeynep Kamil Training and Research Hospital Hynecology and Obstetrics Clinic.
These patients who will have indication for primary cesarean section will be divided into two groups as latent and active phase according to cervical opening and effacement.During cesarean section , tue uterine lower segment transverse incision will be continuously sutured with 1.0 vicryl( with no interlocking).
Also the visceral peritoneum of the vesicle-uterine cavity will be sutured with 2.0 vicryl, This closure technique is to provide hemostasis in the incision.
Also additional single interrupted sutures will be recorded(on the each side and /or in the middle of incision).Also
If additional surgical interventions such as vessel ligation, uterine artery compression sutures ( such as B-Lynch) will be performed during the surgery, the will be recorded.In this study, If the patients with gestational age below 32, confirmed placenta previa or invasion anomaly and a history of previous cesarean section will not be included.All patient's age, gravid , parity, height, weight, gestational week, smoking history, chronic disease such as hypertension, diabetes mellitus, obstetric history such as oligo-polihidroamnios, abortus imminent,etc previous abdominal surgeries, drug use, use of dinoprost(process) for cervical effacement, cervical Foley catheter use, use of oxytocin, duration of labor, presence of early membrane rupture, time interval from the beginning of rupture membrane, presentation, indication for cesarean section, cervikal dilatation and effacement just before the cesarean section, duration of the operation, use of additional uterotonics during the surgery, additional sutures for hemostasis, presence of atony, additional surgical interventions( uterine artery and hypogastric artery ligation, uterine compression sutures), birth weight, preoperative and post hemogram, hematocrit, white blood cell count, platelet count, blood transfusion if it was given, discharge time, and endometriosis will be recorded.
Patients will be called for control examination in the third( 3rd) month after operation.
And patients will be asked about clinical findings such as prolonged menstrual bleeding, midsiklus bleeding, dysmenorrhea, pelvic pain.
At the same time the presence of isthmuses, the depth and the shape of the istmosel pocket and the myometrial thickness will be measured and recorded with transvaginal ultrasound.
Thus, the importance of isthmocele formation on patients who had caeserean section either on latent phase or active phase of labor will be investigated .
In addition , other risk factors leading to isthmocele formation will be investigated.
Study Type
Observational
Enrollment (Anticipated)
320
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Resul Karakus, MD
- Phone Number: 00905059164216
- Email: resul-karakus@hotmail.com
Study Locations
-
-
Uskudar
-
Istanbul, Uskudar, Turkey, 34668
- Recruiting
- Zeynep Kamil Maternity and Childrens Training and Research Hospital
-
Contact:
- Resul Karakus, MD
- Phone Number: 05059164216
- Email: resul-karakus@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant Patients at the age of minimum 18 to 45 and with the gestational weeks between 32 to 41, with no history of caesarean section and no confirmed placenta previa and/or invasion anomaly
Description
Inclusion Criteria:
- Pregnant women with the gestational weeks between 32-41 primigravida or multigravida with no history of caesarean section
Exclusion Criteria:
- Gestational age below 32 weeks
- Confirmed Plasenta Previa and/or placental invasion anomalies
- A history Caeserean Section
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Latent Phase of Labour
|
Active Phase of Labour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Isthmocele Development
Time Frame: 10 months
|
ISTHMOCELE DEVELOPMENT ACCORDİNG TO CERVİCAL DİLATATİON AND EFFACEMENTS
|
10 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Actual)
May 2, 2021
Study Completion (Anticipated)
December 2, 2021
Study Registration Dates
First Submitted
May 12, 2021
First Submitted That Met QC Criteria
May 12, 2021
First Posted (Actual)
May 18, 2021
Study Record Updates
Last Update Posted (Actual)
May 18, 2021
Last Update Submitted That Met QC Criteria
May 12, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- 2020/178
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterus; Scar
-
Assaf-Harofeh Medical CenterNot yet recruiting
-
Gaziosmanpasa Research and Education HospitalCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingCesarean Section Complications | Cesarean Section; Dehiscence | Uterine Bleeding | Uterus; Scar | Uterus AbnormalItaly
-
Institute of Biophysics and Cell Engineering of...Belarusian Medical Academy of Post-Graduate EducationCompletedChronic Endometritis | Uterus; Scar | Uterine Synechiae | Fallopian Tube ObstructionBelarus
-
Ain Shams Maternity HospitalCompleted
-
University of California, DavisCompletedLinear Scar | Zigzag ScarUnited States
-
Mashhad University of Medical SciencesCompletedUterus Contractions Pattern
-
Wake Forest University Health SciencesCompleted
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Kanuni Sultan Suleyman Training and Research HospitalRecruitingUterine Niche | Closure; Incomplete, UterusTurkey